Northwest Biotherapeutics Inc (NWBO) financial statements (2021 and earlier)

Company profile

Business Address 4800 MONTGOMERY LANE
BETHESDA, MD 20814
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:02207221318
Cash and cash equivalents02206221318
Other undisclosed cash, cash equivalents, and short-term investments   1   
Restricted cash and investments   111 
Other undisclosed current assets3210100
Total current assets:32418241519
Noncurrent Assets
Operating lease, right-of-use asset5
Property, plant and equipment000046400
Restricted cash and investments    02 
Deferred costs     2 
Other noncurrent assets110000 
Other undisclosed noncurrent assets0 4745  0
Total noncurrent assets:61484547440
TOTAL ASSETS:9254953715819
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:6161313131710
Accounts payable   1212169
Accrued liabilities   1111
Other undisclosed accounts payable and accrued liabilities61613    
Debt671821111
Deferred compensation liability 0     
Derivative instruments and hedges, liabilities20304052845 
Accrued environmental loss contingencies  6666 
Due to related parties00705  
Business combination, contingent consideration, liability7     
Other undisclosed current liabilities1173311109
Total current liabilities:41708876656920
Noncurrent Liabilities
Long-term debt and lease obligation12233 24 
Long-term debt, excluding current maturities7233 24 
Operating lease, liability5
Liabilities, other than long-term debt    06 
Accrued environmental loss contingencies     6 
Other liabilities    00 
Other undisclosed noncurrent liabilities  6 11(6) 
Total noncurrent liabilities:122931125 
Total liabilities:53729679759320
Temporary equity, carrying amount     29
Stockholders' equity
Stockholders' equity attributable to parent, including:(44)(47)(67)(26)(5)(35)(10)
Common stock1100000
Common stock, share subscribed but unissued, subscriptions receivable(0)(0)     
Additional paid in capital795776722687631486375
Accumulated other comprehensive income (loss)11(1)2(0)(0)(0)
Accumulated deficit(840)(824)     
Other undisclosed stockholders' equity attributable to parent  (789)(715)(635)(521)(385)
Other undisclosed stockholders' equity  20  (2) 
Total stockholders' equity:(44)(47)(47)(26)(5)(37)(10)
TOTAL LIABILITIES AND EQUITY:9254953715819

Income statement (P&L) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Revenue, net01211
Gross profit:2001211
Operating expenses(30)(42)(55)(80)(128)(120)(69)
Other undisclosed operating income     1710
Operating loss:(27)(41)(55)(79)(126)(101)(57)
Nonoperating income (expense)765(12)00(0)
Investment income, nonoperating   (6)   
Foreign currency transaction gain (loss), before tax  5(7)00(0)
Other nonoperating income76   0 
Interest and debt expense(2)0(20)(6)(2)(20)(11)
Loss from continuing operations before income taxes:(22)(36)(71)(98)(128)(121)(69)
Income tax expense     (58) 
Net loss:(22)(36)(71)(98)(128)(178)(69)
Other undisclosed net income (loss) attributable to parent2(0)(3)1814433
Net loss attributable to parent:(20)(36)(73)(80)(115)(136)(66)
Other undisclosed net loss available to common stockholders, basic (18)(1)(6)   
Net loss available to common stockholders, diluted:(20)(54)(74)(86)(115)(136)(66)

Comprehensive Income ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Net loss:(22)(36)(71)(98)(128)(178)(69)
Other comprehensive income (loss)(0)2(2)20 (66)
Comprehensive loss:(22)(34)(73)(96)(128)(178)(135)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent2(0)(3)1814  
Comprehensive loss, net of tax, attributable to parent:(20)(34)(76)(78)(115)(178)(135)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: